CA2408387A1 - A ligand for enhancing oral and cns delivery of biological agents - Google Patents

A ligand for enhancing oral and cns delivery of biological agents Download PDF

Info

Publication number
CA2408387A1
CA2408387A1 CA002408387A CA2408387A CA2408387A1 CA 2408387 A1 CA2408387 A1 CA 2408387A1 CA 002408387 A CA002408387 A CA 002408387A CA 2408387 A CA2408387 A CA 2408387A CA 2408387 A1 CA2408387 A1 CA 2408387A1
Authority
CA
Canada
Prior art keywords
polypeptide
derivative
amino acid
peptide
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002408387A
Other languages
English (en)
French (fr)
Inventor
Lioudmila Tchistiakova
Shengmin Li
Grzegorz Pietrzynski
Valery Alakhov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Supratek Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Supratek Pharma Inc filed Critical Supratek Pharma Inc
Publication of CA2408387A1 publication Critical patent/CA2408387A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/505—Erythropoietin [EPO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
CA002408387A 2001-05-07 2001-05-07 A ligand for enhancing oral and cns delivery of biological agents Abandoned CA2408387A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2001/000926 WO2001090139A2 (en) 2001-05-07 2001-05-07 A ligand for enhancing oral and cns delivery of biological agents

Publications (1)

Publication Number Publication Date
CA2408387A1 true CA2408387A1 (en) 2001-11-29

Family

ID=11004110

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002408387A Abandoned CA2408387A1 (en) 2001-05-07 2001-05-07 A ligand for enhancing oral and cns delivery of biological agents

Country Status (5)

Country Link
EP (1) EP1385873A2 (https=)
JP (1) JP2004514410A (https=)
AU (1) AU2001260526A1 (https=)
CA (1) CA2408387A1 (https=)
WO (1) WO2001090139A2 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7723296B2 (en) 2001-01-18 2010-05-25 Genzyme Corporation Methods for introducing mannose-6-phosphate and other oligosaccharides onto glycoproteins and its application thereof
FR2830016B1 (fr) * 2001-09-27 2004-06-25 Synt Em Compositions pour la vectorisation de derives taxoides a travers la barriere hematoencephalique et leur utilisation pour le traitement des cancers, plus particulierement des cancers du cerveau
EP1877099B1 (en) 2005-04-06 2012-09-19 Genzyme Corporation Therapeutic conjugates comprising a lysosomal enzyme, polysialic acid and a targeting moiety
SI2457920T1 (en) 2007-01-18 2018-02-28 Genzyme Corporation Oligosaccharides containing the amino acid group and their conjugates
CA3040973A1 (en) 2008-12-16 2010-07-01 Genzyme Corporation Oligosaccharide-protein conjugates

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0599303A3 (en) * 1992-11-27 1998-07-29 Takeda Chemical Industries, Ltd. Peptide conjugate
US6635623B1 (en) * 1997-06-13 2003-10-21 Baylor College Of Medicine Lipoproteins as nucleic acid vectors
US6015787A (en) * 1997-11-04 2000-01-18 New England Medical Center Hospitals, Inc. Cell-permeable protein inhibitors of calpain

Also Published As

Publication number Publication date
WO2001090139A3 (en) 2002-06-20
JP2004514410A (ja) 2004-05-20
AU2001260526A1 (en) 2001-12-03
EP1385873A2 (en) 2004-02-04
WO2001090139A2 (en) 2001-11-29

Similar Documents

Publication Publication Date Title
US7112654B2 (en) Ligand for vascular endothelial growth factor receptor
US6696274B2 (en) Ligand for enhancing oral and CNS delivery of biological agents
CN102481341B (zh) 蛋白原及其使用方法
EP3998077B1 (en) Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
US12303546B2 (en) Antimicrobial compositions and methods of use thereof
US20040014652A1 (en) Tumor activated prodrug compounds and methods of making and using the same
JP2003514852A (ja) 炎症反応を阻害する細胞透過性ペプチドおよび使用方法
EP1286700A2 (en) Tumor activated prodrug compounds
KR101898502B1 (ko) 인슐린-유사 성장 인자 1 수용체 결합 펩티드
CA2408387A1 (en) A ligand for enhancing oral and cns delivery of biological agents
JP2006516546A (ja) 間質性膀胱炎の治療用細胞調節性ペプチド
CN112543807B (zh) 片段化的grs多肽、其变体及其应用
JP2004514410A5 (https=)
CN106536548A (zh) Dr3变体及其用途
CA2531228A1 (en) Novel therapeutic fusion proteins
CA2408103A1 (en) Tumor activated prodrug compounds and methods of making and using the same
US20050277575A1 (en) Therapeutic compositions and methods for treating diseases that involve angiogenesis
WO2005009457A1 (en) Rdp58 compositions and methods for inhibiting vascularization of cell populations
CN121627860A (zh) 一种靶向cxcr1/2的母体肽或衍生肽及其应用
CA2399566A1 (en) Par4 peptides and polypeptides
CA2345214A1 (en) Tissue binding peptides, identification, production and utilization thereof

Legal Events

Date Code Title Description
FZDE Discontinued